CONSTRUCTION OF COMPUTER MODEL FOR DIAGNOSTICS AND MONITORING OF NON-ALCOHOLIC FATTY LIVER DISEASE
Keywords:
non-alcoholic fatty liver disease, non-alcoholic steatosis, steatohepatitis, type 2 diabetesAbstract
Timely diagnosis and treatment of non-alcoholic fatty liver disease (NAFLD) are essential to prevent the development of steatohepatitis and liver cirrhosis. This is especially true for patients with type 2 diabetes. The aim of our work was to build a computer model for the diagnosis and monitoring of NAFLD treatment. Materials and methods. The study included more than 55 clinical and laboratory parameters of 233 patients with non-alcoholic steatosis (NAS) and 60 patients with steatohepatitis (NASH). Results. The calculations were based on the levels of systolic blood pressure, erythrocytes, ALT, AST, glutamate dehydrogenase and platelets in persons with type 2 diabetes mellitus with NAS and NASH. The model allows to differentiate NAS and NASH with a sensitivity of 82% and a specificity of 88%.
References
NCD-RisC. Trends in adult body mass index in 200 countries from 1975 to 2014. Lancet 2016, 387, 1377–1396.
Ray, K. NAFLD–The next global epidemic. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 621. [CrossRef] [PubMed]
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
Van Wagner, L.B.; Wilcox, J.E.; Colangelo, L.A.; Lloyd-Jones, D.M.; Carr, J.J.; Lima, J.A.; Lewis, C.E.; Rinella, M.E.; Shah, S.J. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015, 62, 773–783. [CrossRef] [PubMed]
Vanni, E.; Marengo, A.; Mezzabotta, L.; Bugianesi, E. Systemic complications of nonalcoholic fatty liver disease: When the liver is not an innocent bystander. Semin. Liver Dis. 2015, 35, 236–249. [CrossRef] [PubMed]
Kim, D.; Kim, W.R.; Kim, H.J.; Therneau, T.M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013, 57, 1357–1365. [CrossRef] [PubMed]
Haring, R.;Wallaschofski, H.; Nauck, M.; Dorr, M.; Baumeister, S.E.; Volzke, H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50, 1403–1411. [CrossRef] [PubMed]
Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol. 2018;30(10):1103 – 1115. doi:10.1097/ MEG.0000000000001235
Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577 – 1586. doi:10.1002/hep.28785
Rinella ME, Loomba R, Caldwell SH, Kowdley K, Charlton M, Tetri B, Harrison SA. Controversies in the Diagnosis and Management of NAFLD and NASH. Gastroenterology & Hepatology Volume 10, Issue 4 April 2014. P.219-227
Alkhouri N, McCullough AG. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:66-668.
Angulo P, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-789.
Cichoż-Lach H, Celiński K, Prozorow-Król B, et al. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit. 2012;18:CR735-740.
Kruger FC, Daniels CR, Kidd M, et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. S Afr Med J. 2011;101:477-480.
Jayakumar S, Middleton MS, Lawitz EJ, et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70:133-141.
Inoue M, Hayashi A, Taguchi T, et al. Effects of canagli fl ozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease. J Diabetes Investig. Epub 2018 Nov 21.
Sadikova D.Sh., Khaydarova F.A. What is the profile of patients with type 2 diabetes and non-alcoholic fatty liver disease?
Kremer N.Sh. Probability theory and mathematical statistics: Textbook for universities. - M., UNITY-DANA, 2001
Mkhitaryan V.S., Troshin L.I., Adamova E.V., Shevchenko K.K., Bambaeva N.Ya. Probability theory and mathematical statistics / Moscow International Institute of Econometrics, Informatics, Finance and Law. - M., 2002
